The effects of the IRA on our business and the healthcare industry in general is not yet known.
All entries for: Oncology
March 26, 2026
Can-Fite BioPharma Ltd
Neutral Outlook
Petah Tikva, Israel
1-50 employees
On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, which includes several provisions to lower prescription drug costs for people with Medicare, including price negotiation requirements for drugs covered under Medicare, rebate requirements when drug prices rise faster than inflation, and a cap on out-of-pocket spending for Medicare Part D enrollees.
Disease Area: Immune Diseases, Oncology
Drug Type: Small Molecule
March 25, 2026
Atossa Therapeutics, Inc.
Negative Outlook
Seattle, WA
1-50 employees
The taxes imposed by any new federal legislation and the expansion in government’s effect on the U.S. healthcare industry, including the Inflation Reduction Act enacted in August 2022, may result in decreased profits to us, lower reimbursements by payors for our products or reduced medical procedure volumes, all of which may adversely affect our business, financial condition and results of operations.
Disease Area: Oncology
Drug Type: Small Molecule
March 25, 2026
BeyondSpring
Neutral Outlook
Florham Park, NJ
51-200 employees
For example, the Inflation Reduction Act of 2022, or IRA, enacted on August 16, 2022, seeks to reduce prescription drug costs by, among other provisions, allowing Medicare to negotiate prices for certain high-cost prescription drugs in Medicare Parts B and D, imposing an excise tax on pharmaceutical manufacturers that refuse to negotiate pricing with Medicare, requiring inflation rebates to limit annual drug price increases in Medicare, and redesigning the Medicare Part D formula.
Disease Area: Hematology, Oncology
Drug Type: Small Molecule
March 24, 2026
Absci Corp/WA
Neutral Outlook
Vancouver, WA
201-500 employees
The IRA also enacted significant changes intended to reduce prescription drug spending and beneficiary out-of-pocket costs, including redesigning the Medicare Part D benefit beginning in 2025 (including a lower annual out-of-pocket threshold), replacing the prior coverage gap discount framework with a new Part D Manufacturer Discount Program, requiring inflation-based rebates in certain contexts, and establishing a Medicare Drug Price Negotiation Program that permits CMS to set a “maximum fair price” for certain qualifying single-source drugs and biologics reimbursed under Medicare Part B and/or Part D.
Disease Area: Immune Diseases, Oncology
Drug Type: Biologic
March 24, 2026
Curis Inc/MA
Neutral Outlook
Lexington, MA
51-200 employees
Further, with the passage of the Inflation Reduction Act, or the IRA, in August 2022, Congress extended the expansion of PPACA premium tax credits through 2025.
Disease Area: Hematology, Oncology
Drug Type: Small Molecule
March 23, 2026
Xilio Therapeutics
Neutral Outlook
Waltham, MA
51-200 employees
On August 16, 2022, the Inflation Reduction Act of 2022, or the IRA, was signed into law. The new legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B, to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.
Disease Area: Oncology
Drug Type: Biologic